Patents by Inventor Matthias BROCK

Matthias BROCK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250066482
    Abstract: The present invention relates to an isolated antibody which specifically binds human PDL1, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.
    Type: Application
    Filed: September 2, 2024
    Publication date: February 27, 2025
    Inventors: Tea GUNDE, Matthias BROCK, Christian HESS, Alexandre SIMONIN
  • Patent number: 12209133
    Abstract: The present invention relates to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: January 28, 2025
    Assignee: Numab Therapeutics AG
    Inventors: Tea Gunde, Matthias Brock, Christian Hess, Alexandre Simonin, Stefan Warmuth
  • Patent number: 12202911
    Abstract: The present invention relates to a multispecific antibody comprising at least one CD137 binding domain and at least one PDL1 binding domain, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said multispecific antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said multispecific antibody.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: January 21, 2025
    Assignee: Numab Therapeutics AG
    Inventors: David Urech, Tea Gunde, Sebastian Meyer, Matthias Brock, Christian Hess, Alexandre Simonin, Stefan Warmuth
  • Publication number: 20240392003
    Abstract: The present invention relates to a multispecific antibody comprising one or two binding domains, which specifically bind to the extracellular domain of ROR1 (ROR1-BDs), and one binding domain, which specifically binds to CD3 (CD3-BD), wherein the multispecific antibody does not comprise an immunoglobulin Fc region. The present invention further relates to nucleic acids encoding said multispecific antibody, vector(s) comprising said nucleic acids, host cell(s) comprising said nucleic acids or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.
    Type: Application
    Filed: February 2, 2022
    Publication date: November 28, 2024
    Inventors: Bithi CHATTERJEE, Daniel SNELL, Alexandre SIMONIN, Tea GUNDE, Christian HESS, Stefan WARMUTH, Matthias BROCK, Julia TIETZ, Maria JOHANSSON, Fabio Mario SPIGA
  • Patent number: 12077588
    Abstract: The present invention relates to an isolated antibody which specifically binds human PDL 1, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: September 3, 2024
    Assignee: Numab Therapeutics AG
    Inventors: Tea Gunde, Matthias Brock, Christian Hess, Alexandre Simonin
  • Publication number: 20240084039
    Abstract: The present invention relates to antibody variable domains, which exhibit a reduced binding to pre-existing anti-drug antibodies (ADA), and to antibodies comprising one or more of said antibody variable domains The present invention further relates to nucleic acid sequences encoding said antibody variable domains or said antibodies, vector(s) comprising said nucleic acid sequences, host cell(s) comprising said nucleic acids or said vector(s), and a method of producing said antibody variable domains or said multispecific antibodies. Additionally, the present invention relates to pharmaceutical compositions comprising said antibodies and to methods of use thereof.
    Type: Application
    Filed: December 23, 2021
    Publication date: March 14, 2024
    Inventors: Maria JOHANSSON, Julia TIETZ, Stefan WARMUTH, Matthias BROCK
  • Publication number: 20230203162
    Abstract: The present invention relates to a multispecific antibody comprising two antibody-based binding domains, which specifically binds to mesothelin (MSLN-BD); and at least one antibody-based binding domain, which specifically binds to CD3 (CD3-BD); wherein said multispecific antibody does not comprise an immunoglobulin Fc region polypeptide, and wherein each of said MSLN-BD binds to mesothelin (MSLN) with a monovalent dissociation constant (KD) in the range of from 0.5 to 20 nM, when measured by SPR. The present invention further relates to nucleic acid sequence(s) encoding said multispecific antibody, vector(s) comprising aid nucleic acid sequence(s), host cell(s) comprising said nucleic acid sequence(s) or said vector(s), and a method of producing said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said multispecific antibody and methods of use thereof.
    Type: Application
    Filed: May 28, 2021
    Publication date: June 29, 2023
    Inventors: Peter LICHTLEN, David URECH, Christian HESS, Tea GUNDE, Alexandre SIMONIN, Stefan WARMUTH, Matthias BROCK, Bithi CHATTERJEE, Maria JOHANSSON, Daniel SNELL
  • Publication number: 20230192897
    Abstract: The present invention relates to a multispecific antibody comprising at least one CD137 binding domain and at least one PDL1 binding domain, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said multispecific antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said multispecific antibody.
    Type: Application
    Filed: October 9, 2018
    Publication date: June 22, 2023
    Inventors: David URECH, Tea GUNDE, Sebastian MEYER, Matthias BROCK, Christian HESS, Alexandre SIMONIN, Stefan WARMUTH
  • Patent number: 11578133
    Abstract: The present invention relates generally to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof, a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 14, 2023
    Assignee: Namab Therapeutics AG
    Inventors: Tea Gunde, Matthias Brock, Christian Hess, Alexandre Simonin
  • Publication number: 20210395379
    Abstract: The present invention relates to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 23, 2021
    Inventors: Tea Gunde, Matthias Brock, Christian Hess, Alexandre Simonin, Stefan Warmuth
  • Publication number: 20200332015
    Abstract: The present invention relates generally to an isolated antibody which specifically binds human CD137, and pharmaceutical compositions and methods of use thereof, a nucleic acid comprising a nucleotide sequence encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.
    Type: Application
    Filed: October 9, 2018
    Publication date: October 22, 2020
    Inventors: Tea GUNDE, Matthias BROCK, Christian HESS, Alexandre SIMONIN
  • Publication number: 20200283528
    Abstract: The present invention relates to an isolated antibody which specifically binds human PDL 1, and pharmaceutical compositions and methods of use thereof. The present invention further relates to a nucleic acid encoding said antibody, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibody.
    Type: Application
    Filed: October 9, 2018
    Publication date: September 10, 2020
    Inventors: Tea GUNDE, Matthias BROCK, Christian HESS, Alexandre SIMONIN